Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | Q9HBH1 | 1/20 | 0.30 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120630 | 0.81 | PDF (0.40) | CHRNB2CHRNA4CHRNB4TSHRPDF | |
| SCHEMBL29842731 | 0.78 | ALDH1A1 (0.37) | ALOX15 | |
| SCHEMBL21728663 | 0.77 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23055054 | 0.77 | CA1 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3PDF | |
| SCHEMBL287670 | 0.75 | — | — | |
| SCHEMBL10305061 | 0.75 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10305030 | 0.75 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5266422 | 0.75 | BLM (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23055048 | 0.75 | CA1 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15314113 | 0.75 | CHRM1 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019043214-A1 | GLUTARIMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |